Parkinson Platform Noord Nederland

Progressive supranuclear palsy is a rare neurodegenerative disease characterised by an axial parkinsonian syndrome, early falls, supranuclear gaze palsy, and frontal cognitive impairment.1 In these patients, the response to levodopa is poor, and the disease rapidly leads to severe disability and death. Neuropathology shows aggregates of four microtubule-binding-domain-repeat (4R) tau in both neuronal and glial cells, and therefore immunotherapies targeting tau have been proposed as a potential treatment for the disease.